🇺🇸 FDA

Company profile · Sponsor

Galmed

Galmed Pharmaceuticals

GLMD · NYSE pharma RAMAT GAN, L3, USA
Pipeline
13
Drugs
0
Patents
8

Quick answer

Galmed (GLMD) is a pharma company. headquartered in RAMAT GAN, L3, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker GLMD
Exchange NYSE
Company type pharma
Headquarters RAMAT GAN, L3, USA
SEC CIK 0001595353

Pipeline (13)

Search pipeline →

  1. Aramchol free acid

    Galmed

    Nonalcoholic Steatohepatitis (NASH)

    phase 3 small molecule on hold

    1 trial

  2. Aramchol

    Galmed

    Fatty Liver

    phase 2 small molecule completed

    1 trial

  3. Aramchol

    Galmed

    Non-Alcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  4. Aramchol

    Galmed

    Gallstones

    phase 2 small molecule terminated

    1 trial

  5. Aramchol meglumine

    Galmed

    Primary Sclerosing Cholangitis

    phase 2 small molecule terminated

    1 trial

  6. mFOLFOX6 + BIBF 1120

    Galmed

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  7. A study to compare two different aramchol formulations in healthy volunteers.

    Galmed

    Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis

    phase 1 other active

    1 trial

  8. Aramchol

    Galmed

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  9. Aramchol

    Galmed

    Healthy

    phase 1 small molecule active

    4 trials

  10. Aramchol

    Galmed

    NASH

    phase 1 small molecule completed

    1 trial

  11. Aramchol free acid tablet 600mg, single dose

    Galmed

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  12. Aramchol meglumine

    Galmed

    Healthy

    phase 1 small molecule active

    1 trial

  13. amilo-5MER

    Galmed

    Inflammatory Disease

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12239712

    Combination therapy for the treatment of liver disease

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11571431

    Aramchol salts

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11197870

    Treatment for hepatic fibrosis

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11166964

    Treatment for modulating gut microbiota

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10849911

    Low dose compositions of Aramachol salts

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8975246

    Bile acid or bile salt fatty acid conjugates

    Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8110564

    Bile acid or bile salt fatty acid conjugates

    Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7501403

    Bile acid or bile salt fatty acid conjugates

    Expires Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Galmed?

Galmed (GLMD) is a pharma company. headquartered in RAMAT GAN, L3, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Galmed sponsor?

We track 13 ClinicalTrials.gov-linked programs for Galmed, including Aramchol free acid and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Galmed company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.